Literature DB >> 32200803

SnapShot: Natural Killer Cells.

Adeline Crinier1, Emilie Narni-Mancinelli1, Sophie Ugolini1, Eric Vivier2.   

Abstract

NK cells are broadly distributed innate lymphoid cells (ILCs) encompassing distinct populations based on CD11b and CD27 expression in mice or CD56 intensity in humans. Involved in anti-viral and anti-tumor immunity thanks to their cytokines and chemokines secretion as well as their cytotoxic capabilities, NK cells have emerged as a promising therapeutic target in several solid tumors and hematological malignancies. To view this Snapshot, open or download the PDF.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Year:  2020        PMID： 32200803     DOI： 10.1016/j.cell.2020.02.029

Source DB:  PubMed          Journal:  Cell        ISSN： 0092-8674            Impact factor:   41.582


  26 in total

1.  Immunological role and prognostic potential of CLEC10A in pan-cancer.

Authors:  Yan Qin; Lulu Wang; Lihua Zhang; Jiasheng Li; Lixian Liao; Lihaoyun Huang; Wei Li; Jianrong Yang
Journal:  Am J Transl Res       Date:  2022-05-15       Impact factor: 3.940

Review 2.  Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy.

Authors:  Shweta Joshi; Andrew Sharabi
Journal:  Pharmacol Ther       Date:  2022-02-02       Impact factor: 13.400

3.  CCL22 mutations drive natural killer cell lymphoproliferative disease by deregulating microenvironmental crosstalk.

Authors:  Constance Baer; Shunsuke Kimura; Mitra S Rana; Andrew B Kleist; Tim Flerlage; David J Feith; Peter Chockley; Wencke Walter; Manja Meggendorfer; Thomas L Olson; HeeJin Cheon; Kristine C Olson; Aakrosh Ratan; Martha-Lena Mueller; James M Foran; Laura J Janke; Chunxu Qu; Shaina N Porter; Shondra M Pruett-Miller; Ravi C Kalathur; Claudia Haferlach; Wolfgang Kern; Elisabeth Paietta; Paul G Thomas; M Madan Babu; Thomas P Loughran; Ilaria Iacobucci; Torsten Haferlach; Charles G Mullighan
Journal:  Nat Genet       Date:  2022-05-05       Impact factor: 41.307

4.  Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis.

Authors:  Rongqing Pan; Jeremy Ryan; Deng Pan; Kai W Wucherpfennig; Anthony Letai
Journal:  Cell       Date:  2022-04-20       Impact factor: 66.850

5.  The role of NK cells in oncolytic viral therapy: a focus on hepatocellular carcinoma.

Authors:  Frazer Warricker; Salim I Khakoo; Matthew D Blunt
Journal:  J Transl Genet Genom       Date:  2021-08-04

6.  NF-κB c-Rel Is Dispensable for the Development but Is Required for the Cytotoxic Function of NK Cells.

Authors:  Yorleny Vicioso; Derek P Wong; Nand K Roy; Nayanika Das; Keman Zhang; Parameswaran Ramakrishnan; Reshmi Parameswaran
Journal:  Front Immunol       Date:  2021-04-29       Impact factor: 7.561

7.  Rocaglamide promotes the infiltration and antitumor immunity of NK cells by activating cGAS-STING signaling in non-small cell lung cancer.

Authors:  Xuewei Yan; Chao Yao; Cheng Fang; Min Han; Chenyuan Gong; Dan Hu; Weiming Shen; Lixin Wang; Suyun Li; Shiguo Zhu
Journal:  Int J Biol Sci       Date:  2022-01-01       Impact factor: 6.580

Review 8.  Myosin 1g and 1f: A Prospective Analysis in NK Cell Functions.

Authors:  David Cruz-Zárate; Carlos Emilio Miguel-Rodríguez; Irving Ulises Martínez-Vargas; Leopoldo Santos-Argumedo
Journal:  Front Immunol       Date:  2021-12-14       Impact factor: 7.561

Review 9.  The Adverse Impact of Tumor Microenvironment on NK-Cell.

Authors:  Ziming Hu; Xiuxiu Xu; Haiming Wei
Journal:  Front Immunol       Date:  2021-06-11       Impact factor: 7.561

Review 10.  Immunological Drivers in Graves' Disease: NK Cells as a Master Switcher.

Authors:  Daniela Gallo; Eliana Piantanida; Matteo Gallazzi; Luigi Bartalena; Maria Laura Tanda; Antonino Bruno; Lorenzo Mortara
Journal:  Front Endocrinol (Lausanne)       Date:  2020-07-17       Impact factor: 5.555
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.